The orphan-drug exclusion protects anti-C5 pricing while iptacopan creates a new Part D access gap — the US PNH payer landscape is more complex than at any prior point.
Eculizumab and ravulizumab route to Medicare Part B as administered biologics and rank among the highest Part B rare disease expenditures. Despite that spend, both are shielded from Inflation Reduction Act price negotiation by the orphan-drug exclusion, broadened by the 2025 One Big Beautiful Bill Act to cover drugs carrying multiple orphan designations and no non-orphan indication — a definition that captures the entire anti-C5 class (PNH, aHUS, gMG, NMOSD). Neither agent appears on any published CMS selected-drug list (IPAY 2026, 2027, or 2028), and eculizumab is further insulated by approved interchangeable biosimilars (Bkemv, Epysqli, 2024). The price anchor for the class therefore holds: a materially different launch calculus for iptacopan than a negotiated reset would imply.
Iptacopan routes to Medicare Part D as an oral agent, not Part B. This creates a structural out-of-pocket differential: IV anti-C5 under Part B carries no copay for dual-eligible beneficiaries; iptacopan under Part D exposes beneficiaries to the redesigned benefit's annual out-of-pocket cap. ICER's March 2024 evidence report rated iptacopan versus C5 inhibitors in EVH-experienced patients 'Promising but Inconclusive' and found its ~$550,000 annual WAC far above the $156,000–$157,000 health-benefit price benchmark — roughly a 71% discount to reach cost-effectiveness. No major payer had published a formal IV-to-oral switch protocol as of mid-2024.
US PNH agent payer status — 2024
| Drug (Brand / INN) | Benefit Routing | IRA Status | ICER Status | PA Criteria (Commercial) | Key Payer Risk |
|---|---|---|---|---|---|
| Ultomiris (ravulizumab) | Medicare Part B (IV administered) | Excluded — orphan-only (PNH/aHUS/gMG/NMOSD) under OBBBA 2025 | C5 comparator in ICER 2024 review; C5 price called unaligned with benefit | LDH ≥1.5× ULN + FLAER clone ≥10%; tier 2 specialty | Oral iptacopan switching and eventual biosimilars, not IRA, are the price risks |
| Soliris (eculizumab) | Medicare Part B (IV administered) | Excluded — orphan-only indications; approved biosimilars (Bkemv, Epysqli 2024) also bar selection | C5 comparator in ICER 2024 review | LDH ≥1.5× ULN + FLAER clone ≥10%; declining commercial access | Interchangeable biosimilars + ravulizumab/oral switching drive volume erosion |
| Fabhalta (iptacopan) | Medicare Part D (oral agent) | Excluded — orphan-only indications; not on any CMS selected-drug list | ICER Mar 2024: 'Promising but Inconclusive'; ~$550K WAC vs $156K–157K value benchmark | PA forming; no standard step-edit published mid-2024 | Part D OOP burden vs Part B; payer switch criteria gap |
| Piasky (crovalimab) | Medicare Part B (SC maintenance) | Excluded — orphan-only anti-C5; approved Jun 2024 | Not separately assessed by ICER | Equivalent to IV C5 PA; SC self-injection site-of-care savings | Home/self-injection vs clinic cost model — payer preference forming |
Sources: ICER PNH Evidence Report (Iptacopan and Danicopan), March 13, 2024; CMS Medicare Drug Price Negotiation Program selected-drug lists (IPAY 2026–2028) and OBBBA orphan-exclusion guidance; CMS Part B Drug Spending Dashboard; FDA biosimilar approvals (Bkemv, Epysqli); major payer formulary PA policy documents.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Orphan-exclusion analysis for the anti-C5 class under the 2025 OBBBA
- biosimilar-driven eligibility bar for eculizumab
- pricing-parity analysis for IV anti-C5 vs oral iptacopan absent a negotiated reset
Delivers
- Current formulary tier and PA criteria at top 5 US commercial payers
- clinical threshold for IV C5 inadequate response
- EVH Hgb criterion as PA trigger
Delivers
- Medicare OOP comparison: Part B dual-eligible vs Part D redesigned benefit
- commercial OOP tier differential
- payer economic incentive analysis for IV-to-oral switch
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Four FDA-approved anti-complement agents route through different Medicare benefits — Part B for IV Ultomiris, Soliris, Piasky, Part D for oral Fabhalta.
- Why the orphan-drug exclusion, not IRA negotiation, is the single mechanism keeping all four anti-C5 agents off CMS selected-drug lists.
- How the 2025 One Big Beautiful Bill Act broadened the orphan exclusion to capture the entire anti-C5 class.
- Why eculizumab's 2024 interchangeable biosimilars, Bkemv and Epysqli, add a second structural bar to Medicare price negotiation.
- ICER's March 2024 report rated iptacopan 'Promising but Inconclusive' against C5 inhibitors in EVH-experienced PNH patients.
- Why a ~$550,000 annual WAC sits roughly 71% above the $156,000-$157,000 price ICER judged cost-effective.
- Why IV anti-C5 under Part B carries no copay for dual-eligible beneficiaries while oral iptacopan falls under Part D.
- How the redesigned Part D benefit's annual out-of-pocket cap changes the access calculus for an oral complement inhibitor.
- Prior authorization at UHC, CVS/Aetna, Cigna, Anthem, and Humana anchors on LDH at least 1.5x ULN plus a FLAER clone of 10% or more.
- Why no major commercial payer had published a standard step-edit or IV-to-oral switch protocol for iptacopan as of mid-2024.
- Why the ~$550K iptacopan WAC versus the $156K-157K ICER benchmark is the value gap any future contract must bridge.
- How Piasky's subcutaneous self-injection option is already shifting payer site-of-care cost preference ahead of any formal outcomes deal.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
PNH P&HTA is built from ICER evidence reports, CMS IRA negotiation documentation, Medicare Part B and Part D payment dashboards, and live payer formulary and PA policy documents from UHC, CVS/Aetna, Cigna, Anthem, and Humana.
Key sources: ICER PNH Evidence Report (Iptacopan and Danicopan), March 13, 2024; CMS Medicare Drug Price Negotiation Program selected-drug lists (IPAY 2026–2028) and OBBBA orphan-exclusion guidance; CMS Medicare Part B Drug Spending Dashboard; CMS Part D benefit design specifications; major payer PA clinical coverage policies (current versions).
- IRA negotiation status verified against CMS published selected-drug lists (IPAY 2026–2028) and OBBBA orphan-exclusion guidance
- ICER cost-effectiveness data verified against ICER March 2024 PNH Evidence Report (Iptacopan and Danicopan)
- Part B vs Part D routing verified against CMS drug classification criteria
- PA criteria verified against current commercial payer coverage policy documents
Frequently asked questions
Commission this assessment
AXLRx PNH Payer & HTA is built for market access, HEOR, and pricing teams navigating the orphan-drug exclusion for anti-C5, ICER positioning, and the Part B/D oral pivot in the US PNH market. Custom assessment in 72 hours.
Specify indication, payer focus (IRA/orphan exclusion, ICER, PA criteria), and commercial question.
AXLRx analyst confirms payer scope, IRA/orphan-exclusion analysis, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.